Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma

NCT06420349 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06420349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06420349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2024
Completion date
September 9, 2025
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cholangiocarcinoma, metastatic cholangiocarcinoma, refractory cholangiocarcinoma, stage iii hilar cholangiocarcinoma ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv hilar cholangiocarcinoma ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8